MO461FGF19 IMPROVES GLUCOSE METABOLISM IN CKD MICE

Abstract Background and Aims Chronic kidney disease (CKD) is associated with high cardiovascular mortality rate, especially because of altered glucose metabolism insulin resistance. Fibroblast growth factor 19 (FGF19), an intestinal postprandial hormone, has been shown to improve metabolic disturbances In CKD, secretion FGF19 seems blunted in hemodialyzed patients but the role regulation this population unknown. The aim our study ascertain if can homeostasis a mouse model CKD induced by 5/6 subtotal nephrectomy. Method Four weeks post-surgery, mice or sham were treated during 18 days subcutaneous injections placebo human recombinant (0.01mg/kg body weight). effect on was estimated vivo tolerance test (GTT, 1g/kg/body Results Fasted hyperglycemia observed groups compared (151.3 +/- 10.6mg/l 170.7 10.9mg/L, p < 0.001 mice, respectively) tended fasting glycemia (158.9 18mg/L, p<0.09). GTT area under curve (AUC) significantly decreased CKD-FGF19 group (P 0.0001) control = 0.0063). Urea blood level higher (9.6 1.4 mmol/L 25.5 5.6 not affected treatment (24.8 5.8 mmol/L, 0.91). Conclusion Our results show that could contribute intolerance suggest hormone be novel therapeutic target for reducing CKD. comprehension molecular cellular events through which exerted its benefits needs however further studies.